Drugs / INO-1401
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02960594 | Dec 2014 → Nov 2018 | breast cancer, colorectal cancer, esophageal cancer, gastric cancer +5 | Inovio Pharmaceuticals | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2017-11-10 | Inovio Pharmaceuticals | Results Inovio Pharmaceuticals Presents Immuno-Oncology Advancements At Society for Immunotherapy of Cancer Conference inovio.com ↗
Interim results presented at the conference show positive safety and tolerability data as well as the generation of hTERT-specific IFN-γ secreting T cells, suggestive of an ability to break immune tolerance. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2017-11-10 | Inovio Pharmaceuticals | Inovio Pharmaceuticals Presents Immuno-Oncology Advancements At Society for Immunotherapy of Cancer Conference inovio.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | INO-1401 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02960594 ↗ |
| Route | Intramuscular | “2 mg INO-1401 delivered intramuscularly” NCT02960594 ↗ |